Overview
Veracyte Q3 2025 revenue grows 14% yr/yr, beating analyst expectations
Testing revenue increased 17% yr/yr, driven by Decipher and Afirma tests
Company raises full-year revenue and profitability guidance
Outlook
Veracyte raises 2025 testing revenue guidance to $484 mln-$487 mln
Company raises 2025 total revenue guidance to $506 mln-$510 mln
Veracyte increases 2025 adjusted EBITDA guidance to over 25% of revenue
Result Drivers
TESTING REVENUE GROWTH - Driven by 17% increase in testing revenue, led by Decipher and Afirma tests
PRODUCT LAUNCHES - Upcoming launches of TrueMRD and Prosigna LDT expected to support long-term growth
CLINICAL TRIALS - Presentation of Decipher-focused abstracts and completion of NIGHTINGALE trial enhance market leadership
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $131.90 mln | $124.60 mln (9 Analysts) |
Q3 Net Income | $19.10 mln | ||
Q3 Gross Margin | 69% | ||
Q3 Adjusted Operating Expenses | $58.60 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Veracyte Inc is $42.00, about 13.2% above its November 3 closing price of $36.45
The stock recently traded at 49 times the next 12-month earnings vs. a P/E of 38 three months ago
Press Release: ID:nBw5JHRd3a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)